Clinical Trials
21 trialsNCT04447027 2026-01-30
Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT01349959 2025-04-27
Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT03813147 2025-04-13
Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
National Cancer Institute (NCI)
Phase 1 Completed
NCT02828358 2025-02-27
Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement
National Cancer Institute (NCI)
Phase 2 Completed
NCT03092674 2025-01-16
Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
National Cancer Institute (NCI)
Phase 2/3 Completed
NCT03701295 2023-10-18
Pinometostat and Azacitidine in Treating Patients With Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia With 11q23 Rearrangement
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT01168219 2022-08-04
Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00101179 2019-10-18
MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 1 Completed
NCT01281124 2019-09-24
Azacitidine in Treating Patients With Previously Treated Advanced Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00895934 2019-05-23
Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00387465 2019-05-09
Azacitidine and Entinostat in Treating Patients With Recurrent Advanced Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT01249430 2017-09-21
Azacitidine in Combination With Mitoxantrone, Etoposide Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 1 Completed
NCT00313586 2017-02-02
Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT01039155 2015-10-06
Azacitidine and Oxaliplatin In Treating Patients With Advanced Cancers Relapsed or Refractory to Any Platinum Therapy
National Cancer Institute (NCI)
Phase 1 Completed
NCT00351975 2014-12-23
Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases
National Cancer Institute (NCI)
Phase 1 Completed
NCT01105377 2014-08-01
Azacitidine and Entinostat in Treating Patients With Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00004062 2013-12-19
Azacitidine to Restore Thyroid Function in Patients With Persistent or Metastatic Thyroid Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00454480 2013-08-26
Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
National Cancer Institute (NCI)
Phase 2/3 Completed
NCT01235117 2013-08-26
Azacitidine in Treating Patients With Chronic Myelomonocytic Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00006019 2013-06-24
Phenylbutyrate Plus Azacitidine in Treating Patients With Acute Myeloid Leukemia, Myelodysplasia, Non-Hodgkin's Lymphoma, Multiple Myeloma, Non-small Cell Lung Cancer, or Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00217542 2013-05-03
Azacitidine and Recombinant Interferon Alfa-2b in Treating Patients With Stage III or Stage IV Melanoma or Stage IV Kidney Cancer That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 1 Completed